Fresenius SE & Co. KGaA Sponsored ADR (FSNUY)
OTC PINK OTC PINK Primary Summary
Fresenius SE & Co. KGaA (FSNUY) Analyst/Investor Day Transcript
Fresenius SE & Co. KGaA (FSNUY) Analyst/Investor Day Transcript
Fresenius SE & Co. KGaA (FSNUY) Q3 2025 Earnings Call Transcript
Fresenius SE & Co. KGaA (OTCPK:FSNUY) Q3 2025 Earnings Call November 5, 2025 7:30 AM EST Company Participants Nick Stone - Senior VP of Investor Relations & Head of Investor Relations - Fresenius Management SE Michael Sen - CEO, President & Chairman of Management Board of Fresenius Management SE Sara Hennicken - CFO & Member of the Management Board - Fresenius Management SE Conference Call Participants Oliver Metzger - ODDO BHF Corporate & Markets, Research Division Hassan Al-Wakeel - Barclays Bank PLC, Research Division Oliver Reinberg - Kepler Cheuvreux, Research Division Hugo Solvet - BNP Paribas, Research Division Veronika Dubajova - Citigroup Inc., Research Division Graham Doyle - UBS Investment Bank, Research Division Falko Friedrichs - Deutsche Bank AG, Research Division David Adlington - JPMorgan Chase & Co, Research Division Presentation Operator Good afternoon, and welcome to the conference call of Fresenius Investor Relations, which is now starting. May I hand you over to Nick Stone, Head of Investor Relations.
Fresenius: Healthy Portfolio Add
International stocks are essential for portfolio diversification and can provide access to more attractive valuations. Fresenius is a leading global healthcare company with a strong presence and €21.5 billion in annual revenue for 2024. The company specializes in system-critical products and services for critically and chronically ill patients, supporting long-term healthcare trends.
Fresenius SE & Co. KGaA Sponsored ADR (FSNUY) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has Fresenius SE & Co. KGaA Sponsored ADR ever had a stock split?
Fresenius SE & Co. KGaA Sponsored ADR Profile
| Health Care Providers & Services Industry | Healthcare Sector | Mr. Michael Sen CEO | OTC PINK Exchange | US35804M1053 ISIN |
| Germany Country | 177,091 Employees | 27 May 2025 Last Dividend | 5 Aug 2014 Last Split | - IPO Date |
Overview
Fresenius SE & Co. KGaA is a leading health care company specializing in providing a wide range of products and services for chronically ill patients. With its operations divided into four primary segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed, the company caters to the varied needs of patients worldwide. Fresenius Medical Care focuses on offering solutions for those suffering from chronic kidney failure, while Fresenius Kabi is dedicated to the therapy and care of critically and chronically ill patients through its range of drugs, nutrition products, and medical technologies. Fresenius Helios operates clinical and nursing care facilities, and Fresenius Vamed delivers services for hospitals and other healthcare facilities, including operational management. Established in 1912 and formerly known as Fresenius SE, the company underwent a name change in January 2011 to Fresenius SE & Co. KGaA. Headquartered in Bad Homburg vor der Höhe, Germany, Fresenius stands as a testament to innovation and dedication in the healthcare sector.
Products and Services
- Fresenius Medical Care: Focuses on patients with chronic kidney failure, offering dialysis machines, dialyzers, related disposable products, and dialysis-related services. This comprehensive range is designed to improve the quality of life for patients undergoing dialysis treatment.
- Fresenius Kabi: Specializes in the care of critically and chronically ill patients by providing:
- I.V. Generic Drugs: A variety of intravenous generic medications tailored to meet the needs of patients and healthcare providers.
- Biosimilar Drugs: Treatments for autoimmune diseases and oncology, offering cost-effective alternatives to biologic drugs while maintaining quality and efficacy.
- Enteral and Parenteral Nutrition Products: Essential nutrition solutions for patients who cannot eat normally, ensuring they receive the necessary nutrients.
- Medical Technologies and Disposables: Including infusion pumps, apheresis machines, and cell therapy devices, supporting advanced patient care.
- Fresenius Helios: Provides clinical and nursing care facilities, ensuring high-quality care and services for patients and facilitating a holistic approach to health recovery and management.
- Fresenius Vamed: Offers services for hospitals and other healthcare facilities ranging from operational management to comprehensive care services, aimed at optimizing healthcare delivery and patient experience.
